GLEIF
The Global Legal Entity Identifier Foundation (GLEIF) has welcomed the first commercial demonstration of Legal Entity Identifiers (LEIs) embedded within digital certificates by the China Financial Certification Authority (CFCA). Simultaneously, GLEIF confirms that CFCA, which is a member of the GLEIF Certification Authorities (CA) Stakeholder Group, is the newest Validation Agent in the Global LEI System and the inaugural CA to sign up for the Validation Agent role.
These developments by CFCA follow the recent launch of the GLEIF CA Stakeholder Group, created as a platform for GLEIF to collaborate with CAs and Trust Service Providers (TSPs) on the coordination and promotion of a global approach to LEI usage across digital identity products. CFCA’s advances are significant because they are the earliest reported successes aligned to the direction of this industry initiative, which is aimed at achieving a critical mass of LEIs embedded within digital certificates.
Stephan Wolf, CEO of GLEIF comments: “This progress by CFCA on both fronts is very welcome as it moves us one step closer to broad LEI usage in digital certificates globally. Realizing the goal of universal LEI usage in digital identity products will be an important step in enhancing trust and creating innovation opportunities across private sector digital identity management applications. Digital certificates linked by an LEI to verified, regularly updated and freely available entity reference data held within the Global LEI System are easier to manage, aggregate and maintain. The result will be significant efficiencies and far less complexity for certificate owners and the provision of greater transparency for all users of the internet and participants within digital exchanges.”
CFCA demo: Using LEIs to link PDF digital certificates to entity reference data in the central GLEIF database
CFCA has become the first market participant to successfully demonstrate a commercial use case of LEIs being embedded in a digital certificate, specifically within the digital certificate issuance process for PDF documents. CFCA’s TrustSign® PDF software supports digital certificate signing and the demo shows the LEI displayed for users alongside certificate properties inside the software.
CFCA’s TrustSign® software digitally stamps a document with a Digital Business Stamp, which embeds an LEI in accordance with ISO 17442-2. When the document is opened and certificate properties are displayed, the LEI is shown and a link provided, via the GLEIF LEI Lookup API, to the trusted, free and easily accessible entity reference data associated with that LEI, held within the central GLEIF database.
Naijin Lu, from CFCA’s Strategic Development Department, comments: “Incorporating LEI into our digital identity products brings many benefits to certificate users, while being very helpful in constructing a digital identity ecosystem. By using GLEIF API for real-time online verification of LEI-related legal entity information, the advantages of digital certificate and LEI can be well integrated in the practice of digital identity to create a better digital identity authentication experience. We are excited to bring forward the first market-based demo of its kind, which proves that the combination of LEI and digital identity products has a bright future. In the future, we will actively explore other application scenarios of LEI in digital identification field, such as vLEI. “
Prior to CFCA’s demo, and in 2019 and 2020 consecutively, GLEIF had brought forward a Proof of Concept when it published its prior year reports with its LEI embedded within the digital certificates of GLEIF’s signing executive officers. Both instances were prior to the publication of ISO 17442-2 in August 2020 which standardized the process of embedding LEIs in digital certificates.
CFCA becomes a Validation Agent within the Global LEI System
In a complementary development which shows CFCA’s commitment to facilitating and promoting LEI issuance in digital certificates, the organization has become the first CA to become a Validation Agent in the Global LEI System. It partnered with a China based LEI issuer, China Financial Computerization Corp (CFCC), to enable customers to obtain LEIs and include them within CFCA products. This partnership, made possible under the GLEIF Validation Framework, provides CFCA customers with a ‘one-stop-shop’ for obtaining their LEIs alongside their identity authentication and information security services.
The Validation Agent Framework, announced by GLEIF in September 2020 , enables institutions to improve their customer experience, accelerate client lifecycle management and reduce costs by using ‘business-as-usual’, KYC onboarding procedures to facilitate LEI issuance for their clients.
Wolf concludes: “The swift and successful integration of the LEI into CFCA’s TrustSign® software is a hugely exciting innovation, which we hope will be a catalyst for other similar demos related to LEI usage in digital certificates to emerge. It shows what is possible thanks to ISO 17442-2 and demonstrates the LEI’s unique value in this important use case. GLEIF is happy to confirm CFCA as not only our newest Validation Agent within the Global LEI System, but also as the first CA to take up that role. Its partnership with CFCC has made that possible. As momentum builds for the LEI to be used outside of regulatory use cases, thanks to recognition of the opportunity and efficiencies it can offer to the private sector, provision of Validation Agent services by a wide range of key actors in the digital ID management and verification ecosystem will be critical to servicing scaled-up LEI demand and simplifying LEI issuance.
We are excited to learn more about CFCA’s advances through their engagement in the GLEIF CA Stakeholder Group. Their developments get this digital identity industry collaboration off to an incredibly strong start. We look forward to working with CFCA and all members of the CA Stakeholder Group as we jointly set out to advance trust and transparency within digital identity products.”
GLEIF welcomes CAs and TSPs to join and participate in the CA Stakeholder Group’s quarterly meetings. For more information or to join the group, please email info@gleif.org
- ENDS -
Full resolution images and logos can be downloaded via this link
https://www.gleif.org/en/newsroom/gleif-graphics-images
Relevant link
https://www.gleif.org/en
Source:
Global Legal Entity Identifier Foundation, St. Alban-Vorstadt 5, 4052 Basel, Switzerland
Chairman of the Board: Steven Joachim, CEO: Stephan Wolf
Commercial-Register-No.: CHE-200.595.965, VAT-No.: CHE-200.595.965MWST
LEI: 506700GE1G29325QX363
http://bit.ly/1OXTYLo | http://bit.ly/1Me7uZx | GLEIF Blog: http://bit.ly/1LylXkn http://bit.ly/1LylXkn
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005319/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines to Present at Upcoming Investor Conferences28.10.2025 11:01:00 CET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in fireside chats at two upcoming investor conferences: Guggenheim Second Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 9:30 am EST; and Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 4:00 pm GMT/11:00 am EST Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through
Allianz Reports Safety Gains From Automated Mobility and Urges EU-Wide “Driving License” for Autonomous Vehicles28.10.2025 10:05:00 CET | Press release
Strategic priorities for safe autonomous mobility: Allianz calls for EU-wide uniform testing standards for the approval of autonomous vehicles, free access to accident- and safety-related in-vehicle data, and a joint European database for critical traffic situations.Predicted Safety Improvements: Allianz forecasts a 20 percent reduction in traffic accidents by 2035, increasing to over 50 percent by 2060, thanks to autonomous technology.Allianz claims analysis confirms that currently available autonomous braking assistance systems reduce the frequency of specific accidents by 66 percent.Consumer confidence and concerns: A survey across seven European countries reveals that while consumers expect safety improvements, they remain cautious about technological maturity and reliability.Victim protection is essential: Current liability and compulsory insurance models in motor insurance across most EU countries are suitable for autonomous vehicles. The promise of autonomous mobility is not jus
Ares Management and Slate Asset Management to Acquire Polish Real Estate Portfolio Valued at Over €300 Million From Trei Real Estate28.10.2025 09:15:00 CET | Press release
Ares Management Corporation (“Ares”) (NYSE: ARES), a leading global alternative investment manager, and Slate Asset Management (“Slate”), a global investor and manager focused on essential real estate and infrastructure, today announced that a joint venture between Ares Real Estate funds (“Ares Real Estate”) and Slate has agreed to acquire a portfolio of 36 properties in Poland (the “Portfolio”) from Trei Real Estate, an internationally active developer and asset manager. The Portfolio is valued at over €300 million. The Portfolio comprises 36 recently developed and fully occupied convenience-led retail parks strategically located across major Polish metropolitan areas near large catchment populations. The assets are inflation-protected through CPI-linked lease agreements underpinned by tenants with strong covenants. Most of the Portfolio’s income is derived from large regional retailers and essential goods providers, including grocers and pharmacies. “This transaction underlines our c
SK pharmteco Achieves Highest-Level My Green Lab Certifications Across Europe and Asia28.10.2025 09:00:00 CET | Press release
Green certification is the top tier of the globally recognized My Green Lab program for laboratory sustainability excellence SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced a significant milestone in its commitment to environmental sustainability by earning four My Green Lab certifications, including two at the program’s highest level, Green. The remaining two labs earned Gold certification, reflecting advanced sustainability performance and progression toward full Green maturity. The certified facilities are Small Molecule Europe (Swords, Ireland) and Small Molecule Asia (Daejeon, South Korea), and the certifications cover the areas of Quality Control, Process Research & Development, and Analytical Research & Development. My Green Lab certification is widely regarded as the global standard for laboratory sustainability, recognized by the United Nations Race to Zero campaign for its rigor in advancing credible decarbonization. Green ce
Kemwell Biopharma Facility in Bengaluru Successfully Completes U.S. FDA Inspection for Commercial Drug-Product Manufacturing28.10.2025 07:00:00 CET | Press release
Milestone expands India’s role in global biologics manufacturing; collaboration with Cipla underscores commitment to quality and reliability Kemwell Biopharma Pvt Ltd (“Kemwell”), a leading global biologics Contract Development and Manufacturing Organization (CDMO), announced today that its drug-product manufacturing facility in Bengaluru has successfully completed a U.S. Food and Drug Administration (FDA) pre-approval inspection (PAI) and is now cleared for the commercial manufacturing and testing of injectable products destined for the U.S. market. This milestone marks the approval of the first product to get U.S. FDA clearance for commercial supply from Kemwell’s Bengaluru drug-product facility since the site became a dedicated biologics campus eight years ago. It demonstrates the company’s ability to meet stringent current Good Manufacturing Practice (cGMP) and aseptic drug-product manufacturing standards. “Achieving FDA clearance for commercial manufacturing from our Bengaluru sit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
